X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
By utilizing MRI’s internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI’s drug development pipeline including MAN-01 and companion diagnostics, are estimated to achieve a net present value.
Lead Product(s): MAN-01
Therapeutic Area: Ophthalmology Product Name: MAN-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mannin Research
Deal Size: $42.3 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022
Details:
Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib adverse effects.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oklahoma Medical Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Lead Product(s): Strontium-89 Chloride
Therapeutic Area: Musculoskeletal Product Name: Metastron
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chengdu Syncor Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 07, 2022
Details:
MAN-19 therapeutic is a recombinant fusion protein that treats the patient, instead of targeting the virus. It is not a cure for COVID, but it strengthens a patient's blood vessels and protects them against ARDS, breathing problems, sepsis and other infections.
Lead Product(s): MAN-19
Therapeutic Area: Infections and Infectious Diseases Product Name: MAN-19
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mannin Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Lead Product(s): Strontium Chloride, Sr-89
Therapeutic Area: Oncology Product Name: Metastron
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: isoSolutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2021
Details:
Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.
Lead Product(s): Strontium Chloride, Sr-89
Therapeutic Area: Oncology Product Name: Metastron
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clionix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 12, 2021
Details:
The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Uttroside-B
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
Human and genetic studies, as well as animal models of endothelial dysfunction collectively suggest that by targeting Tie2 receptor, MAN-19 may be effective in the treatment of a number of complications associated with viral infections such as COVID-19 and seasonal flu.
Lead Product(s): MAN-19
Therapeutic Area: Infections and Infectious Diseases Product Name: MAN-19
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The Joint venture will deploy Cyclica's unique AI platform to accelerate the development of new treatments based on Mannin's Tie2 based platform.
Lead Product(s): COVID-19 drug
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
